Clinical Trial Update: Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune® [Phase 2]

View source ↗

Summary

Phase 2 trial assessing how long antibodies persist after a single dose of Menactra or Menomune in adolescents and adults aged 15 to 23.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningitis
• Meningococcal Infections

Drugs mentioned

• Menactra (Meningococcal conjugate vaccine (A, C, W, Y))
• Menomune (Meningococcal polysaccharide vaccine (serogroups A, C, W, Y))

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Meningitis, Meningococcal Infection | Phase 2 | Status: COMPLETED | Results posted: 2009-12-14